Skip to main content
. Author manuscript; available in PMC: 2010 Jul 13.
Published in final edited form as: Sci Transl Med. 2010 Apr 21;2(28):28ra29. doi: 10.1126/scitranslmed.3000522

Fig. 7.

Fig. 7

Abcc8-AS and glibenclamide preserve neurological function after SCI. (A) Image captured from movie S1 depicting spontaneous locomotor activity 1 week after C7 hemicord SCI in rats administered Abcc8-Scr (upper tank) or Abcc8-AS (lower tank) for 24 hours after SCI (five rats per group). All subsequent panels in this figure are from these same rats. (B) Truncal stability, performance on up-angled plane, beam walking, and ipsilateral and contralateral hindlimb BBB scores (score in uninjured rats, 21), measured at the times indicated after SCI. For all tests, treatment groups at each time were significantly different (P < 0.01, except for weeks 4 and 5 for angled plane). (C) Quantified spontaneous rearing, measured at the times indicated after SCI, in rats administered Abcc8-AS versus Abcc8-Scr, or glibenclamide (GLIB) versus vehicle (Veh), as indicated. Treatment groups at each time were significantly different (P < 0.01). (D) Low-power views of sections stained with H&E 6 weeks after SCI. Lesion areas and volumes are also shown, as are lesion volumes for rats administered glibenclamide or vehicle, as indicated (five rats per group). Data are expressed as the mean ± SEM. ***P < 0.001.